Wall Street Titan
Contributor since: 2011
Articles
Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Athersys Shares Are Ready To Rumble Following Period Of Turmoil
AVITA Medical Gains FDA Expanded Labels In 'Better Mousetrap' Burn Treatment
Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
Update On Athersys - Trying To Read Between The Lines
Marketplace Contributors 2021 Top Ideas - Part 2
2021 Roundtable: General Outlook - Biotech And Healthcare Investing
2021 Roundtable: Vaccine News - Biotech, Tech, Growth, And Energy Stock Analysis
Mesoblast Needs A Solution To MSC Scalability Issues - Cynata Therapeutics Has An Answer
ThermoGenesis Holdings: Many Short-Term Catalysts In Low-Float Stock
5 Stem Cell Companies Racing Towards COVID-19 ARDS Therapy
Athersys Sees 4 Million Share Insider Buy From Partner Running COVID-19 ARDS Trial In Japan
Athersys - Now In Play For COVID-19 - FDA Fast Tracked Therapy For ARDS
Avita Medical Enters 2020 With Great Momentum
Biotech In 2020: M&A And Gene Therapy In Focus
The Reincarnation Of ThermoGenesis With A Better Mousetrap For CAR-T Manufacturing
The Stem Cell Triple Play Revisited
The Stem Cell Triple Play: 3 Companies With Great Value Drivers
Avita Medical: A Better Mousetrap With FDA Approval To Treat Patient Burns
Keeping Focused Amidst The Biotech Bear
Athersys: A Lucrative China Stem Cell Licensing Deal Seems Imminent
An Interview With Athersys' CEO
Mesoblast Signs Deal In China For Stem Cell Heart Therapies
Athersys/Healios Warrant Structure Bullish For Athersys Shares
Athersys Gets $56 Million From Healios In Stem Cell Deal
A Deep Drill Down To Walmart's Problem In E-Commerce
Athersys Poised For Lucrative Stem Cell Stroke Partnership This Year
BrainStorm Cell Therapeutics ALS Data Not As Promising As Press Releases Indicate
President Obama Signs 21st Century Cures Act - Implications For The Stem Cell Sector
Marketplace Roundtable: The State Of Biotech
All Systems Go On Athersys Pivotal Stem Cell Stroke Trial In Japan - Exploring The Scientific Evidence
Brainstorm Cell Therapeutics: Caution Ahead Of ALS Phase II Data
Stem Cell Company Athersys Firing On All Cylinders In 2016
Cytori Cell Therapy Shows Promising Results In The Erectile Dysfunction Stem Cell Study
Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again
Top Stock Idea For 2016? - Athersys, A Beaten Down Stem Cell Stock With Great Upside
Ocata Management Pulls Out All Stops To Push Astellas Merger Forward
Stem Cell Company Cesca Therapeutics' Bad Idea
Astellas To Acquire Stem Cell Company Ocata Therapeutics At 90% Premium - What Does It Mean For The Stem Cell Sector?
WST Exclusive: Why Chugai And Athersys Parted Ways On Japan Stroke Stem Cell Program